Psoriatic arthritis is a chronic inflammatory arthropathy associated with skin psoriasis. It is considered a unique arthropathy with distinct clinical and radiologic features. Up to 40% of patients with psoriasis may develop psoriatic arthritis. Psoriasis usually precedes psoriatic arthritis, so dermatologists are in a critical position for screening patients of psoriatic arthritis early in the disease course. Psoriatic arthritis may be challenging to diagnose, especially for dermatologists, because it has an insidious disease course, non-specific symptoms, and no specific biomarkers. Psoriatic arthritis is a polygenic autoimmune disorder of unknown etiology, but immunologic roles have recently been validated. In recent years, treatment modalities have rapidly advanced in the fields of psoriasis and psoriatic arthritis. Biologic agents, including TNF-α inhibitors and anti-IL12/23 agents, have shown dramatic improvement.
INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Although PsA was once described as a variant of rheumatoid arthritis (RA), it has been included in the group of spondyloarthropathies. PsA was first defined by Moll and Wright in 1973 in patients who were seronegative for rheumatoid factor (RF) with positive history of psoriasis, current skin or nail psoriasis, and inflammatory joints of axial disease [1] .
The exact estimation of PsA prevalence among psoriasis patients is difficult because several epidemiologic studies on PsA have not used validated criteria. In addition, PsA may present with considerable geographic variations in occurrence [2] . However, recent estimates of epidemiology might reflect an increasing recognition of the disease. PsA incidence has increased from 5% to 40% among patients with psoriasis [2] [3] [4] [5] . Because PsA might be as common as psoriasis, it should not be overlooked.
Approximately 40% to 60% of PsA patients develop erosive arthropathy, and 17% have five or more deformed joints [6, 7] . A delay in diagnosis and treatment may lead to erosive arthropathy, further progressing to physical disability and deformities [4] . Dermatologists who lack expertise in PsA might miss an opportunity for early treatment that could prevent functional joint disability. Unfortunately, many dermatologists are indifferent to psoriatic arthritis with any degree of severity and instead search for signs of hidden arthritis or skin disorders.
CLASSIFICATION AND DIAGNOSIS
The association between arthritis and psoriasis was first described by Alibert in 1818 and was designated psoriasis arthritique by Bazin in 1860 [8] . At that point, distinctive arthritis associated with psoriasis became widely accepted. However, in the 1950s, PsA was grouped with RA as a "rheumatoid
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Lifestyle Medicine Table 1 . CASPAR criteria (modified for dermatologists) for diagnosing psoriatic arthritis Psoriasis (skin and/or scalp) patients with inflammatory joint diseases, spine or tendes/enthesis can be diagnosed with psoriatic arthritis if they fit at least one of the following categories:
Psoriatic nail dystrophy Negative test result for rheumatoid factor Dactylitis (now or in patient's history) Radiologic evidence of juxta-articular new bone formation variant" or "rheumatoid spondylitis" [8] . Subsequently, the distinct nature of PsA was emphasized using clinical criteria. 
PATHOGENESIS
PsA is a polygenic autoimmune disorder of unknown etiology in which genetic susceptibility, environmental factors, and immune mechanisms play crucial roles [9] . Human leukocyte antigen (HLA)-C within the major histocompatibility complex (MHC) region is the strongest genetic association for PsA. Other class I HLA antigens associated with
PsA include HLA-B13, B27, B38, B39, and B57. HLA-B27
is present in 20% to 60% of PsA patients, with increased incidence in the axial or spondylitic forms. HLA-B38 and B39 are most strongly associated with peripheral arthritis [8] . Regarding HLA class II molecules, DR4 is more commonly found in the erosive form, while DR7 is more commonly found in peripheral involvement [8] . HLA-B27 prevalence is much lower in axial PsA than in ankylosing spondylitis (AS), and it is strongly influenced by ethnicity [13, 14] .
Regarding immunopathogenesis, there is prominent lymphocytic infiltrate in both the skin and joints that is localized to dermal papillae in the skin and the sublining layer Moll and Wright emphasized asymmetric arthritis as the most frequent pattern in PsA [1] . Several other recent studies confirm that asymmetric oligoarthritis is the most common pattern in early phase PsA [3, 18] . Involved joints in PsA are usually less tender, less swollen, and less symmetric than in RA. As mentioned above, there might be ethnic differences in the pattern of joint involvement. In a Korean study, axial PsA was the major pattern [13] . Patients with oligoarticular peripheral PsA seem to have a shorter disease duration than patients with polyarthritis [6, 19] .
DIP arthritis and arthritis mutilans represent distinctive features of PsA. In the largest clinical series, DIP arthritis was reported in 1% to 59% of patients with PsA. In this series, disease duration increased with frequency. DIP arthritis is often associated with dactylitis and nail dystrophy [20, 21] . Dystrophic nail changes, including pitting, subungal hyperkeratosis, and transverse grooves, are more frequent in PsA than psoriasis [8] . In roughly 5% of patients with longstanding disease, erosive arthritis causes complete resorption of the entire phalanges. This leads to characteristic clinical features of 'falling joints' or 'opera glass fingers', which is termed arthritis mutilans [22] . than those of upper limbs. Enthesitis represents a hallmark of the clinical features of PsA and is now regarded as the primary lesion [9] . Achilles tendon enthesitis usually coexists with tenosynovitis and contributes to the 'bomb-shaped' tendon [18] .
Dactylitis is defined as diffuse swelling of a digit, or 'sausage-shaped digit' (Fig. 1) . It may occur in one or more digits concomitantly with the typical signs of inflammation, such as swelling, redness, pain, warmth, and limited range of motion. Dactylitis has long been recognized as one of the cardinal features of PsA [1] . It is an expression of active PsA and will respond well to anti-TNF-α therapy [24] . Table 2 compares PsA with other rheumatologic conditions.
Skin lesions such as psoriasis can be localized, diffuse, guttate, or pustular (Fig 2) . There is no specific skin involvement associated with a certain pattern of joint involvement.
Thus, patients with any pattern and degree of arthritis can develop psoriasis vulgaris, severe generalized pustular psoriasis, or erythrodermic psoriasis [8] . Iridocyclitis represents the most frequent extra-articular feature, with an estimated prevalence of 2% to 25% of cases [6, 7, 9, 19] . Iridocyclitis is characterized by an acute onset over 1-2 days, eye pain, redness, miosis, photophobia, and vision blurring.
CONCLUSION
What is the role of dermatologists in the field of PsAscreening, diagnosis, or management? Some assert that if the primary problem is skin psoriasis, PsA can be managed by a dermatologist. If the chief complaint is a joint symptom, rheumatologists should primarily manage the patient with dermatologists assisting in the diagnosis of skin psoriasis [8] .
Dermatologists can conduct a full screening and confirm PsA in psoriasis patients who are visiting a dermatologic department. When managing PsA, oligo-and DIP arthritis can be managed by dermatologists, whereas polyarthritis, spondylitis, and arthritis multilans should be referred to rheumatologists (Fig. 3) .
Recently, more physicians have become aware of the relationship between PsA, artherosclerosis, and increased cardiovascular risk in patients with PsA. Psoriasis and PsA should no longer be regarded as diseases limited to joint or skin. They should be accepted as systemic disorders. Clinical dermatologists should be thoroughly aware of the nature of PsA, and an interdisciplinary approach is needed.
